and inhibits Th17 cells. The immune-modulatory role of vitamin D in chronic kidney disease (CKD) and renal
transplant patients is unclear. We measured whether different serum levels of vitamin D were associated with an
increased or decreased presence of lymphocyte subsets including Treg and Th17 cells in end-stage renal disease
(ESRD) and renal transplant recipients.
Methods: Eighty-seven renal transplant recipients and 53 end-stage renal disease (ESRD) patients were enrolled
in this study. The absolute counts of CD4+ and CD8+ T, CD16+ CD56+ NK, CD19+ B, CD4+ CD25+
CD127- Foxp3+ (Tregs), Helios+ Tregs, CD38+ Tregs, and CD4+ CD17+ (Th17) cells were analyzed in
peripheral blood in both patient groups. In addition, serum 25 (OH) D3, 1, 25 (OH)2 D3, IL-6, IL-17, IL-23, and
TGF-β1 were measured. The association between lymphocyte subset counts and 1, 25 (OH)2 D3 or 25 (OH) D3
was studied, as was the association between serum IL-6, IL-17, IL-23, or TGF-β1 and 1,25 (OH)2 D3 or 25 (OH)
D3.
Results: Serum 25 (OH) D3 and 1,25 (OH)2 D3 levels were not independently associated with peripheral CD4+
T, CD19+B, CD16+CD56+NK, Treg, or Th17 cell counts. In contrast to serum 25 (OH) D3, serum1, 25 (OH)2
D3 was positively associated with CD8+ T cells counts in renal transplant recipients.
Conclusion: Our findings indicate low utility of serum 25 (OH) D3 and 1, 25 (OH)2 D3 levels in predicting a
change in lymphocyte subset counts in ESRD and renal transplant patients.